34. 神経線維腫症 Neurofibromatosis Clinical trials / Disease details


臨床試験数 : 133 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01419639
(ClinicalTrials.gov)
October 201117/8/2011Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2Neurofibromatosis Type IIDrug: Everolimus (RAD001) , Afinitor®New York University School of MedicineNovartis Pharmaceuticals;The Children's Tumor FoundationCompleted3 YearsN/AAll10Phase 2United States
2EUCTR2011-002228-42-FR
(EUCTR)
29/08/2011N/AN/A - AFINF2
MedDRA version: 14.0;Level: PT;Classification code 10029268;Term: Neurofibromatosis;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Cancer [C04]
Trade Name: Afinitor
Product Name: Afinitor
INN or Proposed INN: Evérolimus
Other descriptive name: RAD001
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNot RecruitingFemale: yes
Male: yes
Phase 2France